The estimated Net Worth of Gail K Naughton is at least $114 millier dollars as of 18 August 2022. Gail Naughton owns over 1,984 units of TherapeuticsMD stock worth over $6,973 and over the last 10 years he sold TXMD stock worth over $107,322. In addition, he makes $0 as Independent Director at TherapeuticsMD.
Sign up
Gail Naughton TXMD stock SEC Form 4 insiders trading
Gail has made over 6 trades of the TherapeuticsMD stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 3,922 units of TXMD stock worth $20,630 on 7 December 2022.
The largest trade he's ever made was exercising 96,864 units of TherapeuticsMD stock on 10 August 2021 worth over $172,215. On average, Gail trades about 5,841 units every 132 days since 2014. As of 18 August 2022 he still owns at least 3,922 units of TherapeuticsMD stock.
You can see the complete history of Gail Naughton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gail Naughton biography
Dr. Gail K. Naughton Ph.D. serves as Independent Director of the Company. Dr. Naughton has served as the Chief Scientific Officer and Chief Business Development Officer of Histogen, a company she founded which is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions, since April 2017. Dr. Naughton served as the Chairman and Chief Executive Officer of Histogen from June 2007 until April 2017. Prior to Histogen, Dr. Naughton was the Vice Chairman of Advanced Tissue Sciences, Inc., a human-based tissue engineering company, from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and Executive Vice President, Chief Operating Officer from 1991 to 1995. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica’s TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering. Dr. Naughton received her B.S. in Biology from St. Francis College, her M.S. in Histology and her Ph.D. in Hematology from the New York University Medical Center and her E.M.B.A. from UCLA.
How old is Gail Naughton?
Gail Naughton is 64, he's been the Independent Director of TherapeuticsMD since 2020. There are 3 older and 22 younger executives at TherapeuticsMD. The oldest executive at TherapeuticsMD, Inc. is Tommy Thompson, 78, who is the Independent Chairman of the Board.
What's Gail Naughton's mailing address?
Gail's mailing address filed with the SEC is C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL, NJ, 07974.
Insiders trading at TherapeuticsMD
Over the last 13 years, insiders at TherapeuticsMD have traded over $60,334,483 worth of TherapeuticsMD stock and bought 3,746,989 units worth $33,644,571 . The most active insiders traders include Cooper C. Collins, Brian Bernick et Robert G Finizio. On average, TherapeuticsMD executives and independent directors trade stock every 30 days with the average trade being worth of $233,918. The most recent stock trade was executed by Cooper C. Collins on 22 August 2024, trading 4,094 units of TXMD stock currently worth $7,083.
What does TherapeuticsMD do?
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
What does TherapeuticsMD's logo look like?
Complete history of Gail Naughton stock trades at Cel-Sci et TherapeuticsMD
TherapeuticsMD executives and stock owners
TherapeuticsMD executives and other stock owners filed with the SEC include:
-
John Milligan,
President, Secretary -
Brian Bernick,
Co-Founder -
Robert Finizio,
Chief Executive Officer and Director -
Robert G. Finizio,
Co-Founder & Vice Chair -
Mitchell Krassan,
Chief Strategy and Performance Officer -
John C. K. Milligan IV,
Chief Exec. Officer of VitaCare Prescription Services -
Michael Donegan,
Vice President - Finance -
Tommy Thompson,
Independent Chairman of the Board -
Cooper Collins,
Independent Director -
J. Martin Carroll,
Independent Director -
Angus Russell,
Independent Director -
Jules Musing,
Independent Director -
Dr. Brian A. Bernick,
Co-Founder & Chief Scientific Officer -
Nichol Ochsner,
Vice President, Investor Relations -
Gail Naughton,
Independent Director -
Karen Ling,
Independent Director -
Paul Bisaro,
Independent Director -
Bharat Warrier,
Chief Manufacturing Officer -
Sebastian Mirkin,
Chief Medical Officer -
Dawn Halkuff,
Chief Commercial Officer -
Marlan Walker,
General Counsel -
John Knighton,
Chief Compliance Officer -
Adam Miller,
Chief Information Officer -
James D'Arecca,
Chief Financial Officer -
Julia M. Amadio,
Chief Product Officer -
Mitchell L. Krassan,
Exec. VP and Chief Strategy & Performance Officer -
Michael Donegan,
Chief Accounting Officer & VP of Fin. -
James C. D'Arecca,
Chief Financial Officer -
Hugh O'Dowd M.B.A.,
Pres, CEO & Director -
Robert V Jr La Penta,
Director -
Nicholas Segal,
Director -
Daniel A Cartwright,
Chief Financial Officer -
Capital Management Lp Rosen...,
-
Jane F Barlow,
Director -
Samuel A Greco,
Director -
Randall S Stanicky,
Director -
Edward Borkowski,
EVP, Operations -
Hugh O'dowd,
Chief Executive Officer -
Mark A Glickman,
Co-Chief Executive Officer -
Joseph Ziegler,
Principal Financial Officer